Citius regains compliance with Nasdaq minimum bid price requirement

Citius Pharmaceuticals, Inc.

Nasdaq confirmed compliance with Listing Rule 5550(a)(2) after 10 consecutive trading days with bid price at $1.00 or greater.
Compliance period from June 20, 2025 to July 3, 2025; previously scheduled hearing panel cancelled.
CTXR common stock will continue to be listed and traded on Nasdaq Capital Market.
Chairman and CEO Leonard Mazur stated the company remains focused on critical care products and shareholder value.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.